Three articles published by the research groups led by Yun-Bo Shi of the National Institute of Child Health and Human Development, National Institutes of Health, USA; Aria Baniahmad of the Institute of Human Genetics, Jena University Hospital, Germany; and Kuanyu Li of the Nanjing University Medical School, China, have been selected as the recipients of the 2020 Ming K. Jeang Award for Excellence in Cell and Bioscience.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672483PMC
http://dx.doi.org/10.1186/s13578-021-00727-wDOI Listing

Publication Analysis

Top Keywords

2020 ming
8
ming jeang
8
excellence cell
8
cell bioscience
8
jeang awards
4
awards excellence
4
bioscience three
4
three articles
4
articles published
4
published groups
4

Similar Publications

Objective: To analyze the temporal trends of oral anticoagulant (OAC) prescription, direct oral anticoagulant (DOAC) dose, clinical outcomes and factors associated with non-anticoagulation in patients with incident atrial fibrillation (AF).

Patients And Methods: During January 1, 2011, to December 31, 2020, a total of 249,107 patients with newly diagnosed AF were identified, and the 1-year risks of ischemic stroke, intracranial hemorrhage (ICH), and all-cause mortality were analyzed.

Results: OAC prescription increased from 22.

View Article and Find Full Text PDF

Bipolar disorder is a leading contributor to the global burden of disease. Despite high heritability (60-80%), the majority of the underlying genetic determinants remain unknown. We analysed data from participants of European, East Asian, African American and Latino ancestries (n = 158,036 cases with bipolar disorder, 2.

View Article and Find Full Text PDF

Background: Polypharmacy (i.e., treatment with ≥ 5 drugs) is common in patients with atrial fibrillation (AF) and has been associated with suboptimal management and worse outcomes.

View Article and Find Full Text PDF

A real-world study to evaluate effectiveness of mepolizumab in treating severe asthma in Taiwan (REMIT).

Ther Adv Respir Dis

January 2025

Department of Chest Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shipai Road, Beitou District, Taipei City 11217, Taiwan.

Background: REMIT is the first real-world study of mepolizumab effectiveness in patients with severe asthma (SA) in Taiwan.

Objectives: The primary objective evaluated changes in clinically significant exacerbations (CSEs; defined as use of oral corticosteroids (OCS) or emergency department (ED) visits and/or hospitalizations) in the 12 months pre- and post-mepolizumab treatment. Secondary objectives assessed changes in the number of CSEs requiring ED visits/hospitalizations and daily maintenance OCS (mOCS) dosage 12 months pre- and post-mepolizumab treatment.

View Article and Find Full Text PDF

Background: Many studies have reported the renal outcomes and metabolic consequences after augmentation cystoplasty (AC), however few studies have discussed changes in renal tubular function. The aim of this study was to determine the prevalence of metabolic disturbances, evaluate renal tubular function and 24-hour urine chemistry to evaluate the association between metabolic alterations and urolithiasis after AC.

Methods: We investigated serum biochemistry, blood gas, and 24-hour urinary metabolic profile of children who underwent AC between January 2000 and December 2020.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!